0001209191-23-056237.txt : 20231121
0001209191-23-056237.hdr.sgml : 20231121
20231121161527
ACCESSION NUMBER: 0001209191-23-056237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231117
FILED AS OF DATE: 20231121
DATE AS OF CHANGE: 20231121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yu Yong
CENTRAL INDEX KEY: 0001937482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41599
FILM NUMBER: 231428302
MAIL ADDRESS:
STREET 1: C/O GENELUX CORPORATION
STREET 2: 2625 TOWNSGATE ROAD, SUITE 230
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER NAME:
FORMER CONFORMED NAME: Yu Tony
DATE OF NAME CHANGE: 20220711
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENELUX Corp
CENTRAL INDEX KEY: 0001231457
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2625 TOWNSGATE ROAD, SUITE 230
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-267-9889
MAIL ADDRESS:
STREET 1: 2625 TOWNSGATE ROAD, SUITE 230
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: GENELUX CORP
DATE OF NAME CHANGE: 20030508
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-17
0
0001231457
GENELUX Corp
GNLX
0001937482
Yu Yong
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD, SUITE 230
WESTLAKE VILLAGE
CA
91361
0
1
0
0
VP, Clinical Trial Operations
0
Common Stock
2023-11-17
4
S
0
3541
13.0386
D
102594
D
Common Stock
2023-11-20
4
S
0
14594
11.2554
D
88000
D
The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Sean Ryder, Attorney-in-Fact
2023-11-21